OPKO Health, Inc. Overview
Pro stress-test →OPKO Health is a medical test and medication company focused on diagnostics and pharmaceuticals. The company is undergoing a fundamental strategic shift, deprioritizing its legacy diagnostics business to fuel an ambitious and advancing R&D pipeline. With a portfolio spanning established renal therapies to next-generation multispecific antibody programs, OPKO is repositioning itself as a biopharma innovator.
Strategic Profile
Pro stress-test →Full-year R&D expenses surged 17.9% to $124.0 million, while SG&A expenses fell 26.7%, reflecting a clear capital reallocation toward innovation. The Regeneron partnership provides crucial external validation for OPKO's ModeX MSTAR platform and includes an upfront payment, potential milestones exceeding $200 million per program, and tiered royalties. This positions OPKO as a development partner leveraging proprietary platform technologies with established pharma partners.
Competitive Landscape
Pro stress-test →OPKO's flagship RAYALDEE is the first and only FDA-approved treatment for a specific form of secondary hyperparathyroidism, giving it a unique position in its niche. In multispecific antibodies and GLP-1 analogs, OPKO competes indirectly through partnerships with Regeneron and Entera Bio rather than head-to-head competition. The diagnostics segment faces ongoing pressure from lab consolidation and pricing pressures.
Industry Context
OPKO Health, Inc. operates in Biopharmaceuticals and Medical Diagnostics.
Key facts
Founded: 2007 · Headquarters: Miami, Florida, US · Revenue: $606.9B (2025)